Clinical trials: Soft-tissue Sarcoma
Ewing's Sarcoma, Rhabdomyosarcoma
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
This is a single arm study. The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides.
- Trial name
- NCT00001566
- Testing
- therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Clear Cell
Study on TSR-042 in Advanced Clear Cell Sarcoma
Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).
- Trial name
- ACCeSs (NCT04274023)
- Testing
- TSR-042
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Italian Sarcoma Group
Leukemia, Lymphoma
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00324779
- Testing
- rituximab
- Where
- 38 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- University Hospital Erlangen
Sarcoma
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial…
- Trial name
- NCT00642941
- Testing
- RG1507
- Where
- 41 sites in United States, Australia and 9 more
- Volunteers
- 317 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
This was a phase 1, open-label, multiple dose, single-arm study. The mixed bacteria vaccine (MBV) was administered at a starting dose of 250 EU (1 µL) and escalated in each subject to a dose inducing the desired pyrogenic effect…
- Conditions
- Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer
- Trial name
- NCT00623831
- Testing
- Mixed bacterial vaccine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ludwig Institute for Cancer Research
Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment.
- Trial name
- NCT03896620
- Testing
- Preoperative RT, Postoperative RT, Chemotherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Medical College of Wisconsin
Soft Tissue Sarcoma
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
This is a two center, 2 arm, Phase II study evaluating the combination of Ribociclib and Everolimus in patients with advanced DDL and LMS who have had at least 1 prior systemic therapy.
- Trial name
- NCT03114527
- Testing
- Ribociclib, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fox Chase Cancer Center
Primary Retroperitoneal Sarcoma
Survival and Prognostic Factors of Primary Retroperitoneal Sarcomas After Surgery: a Single-center Experience
he percentage of retroperitoneal sarcomas (RPS) among all soft tissue sarcomas ranges from 10%-15%. Surgery remains the gold standard for RPS.
- Trial name
- NCT06396962
- Testing
- WANG DAORONG
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Northern Jiangsu People's Hospital
Sarcoma
Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma
This is a single-center, single-arm phase Ib / II clinical trial, which was included with two phase. The main purpose of the phase Ib part was to determine the dose-limiting toxicity ( DLT ), maximum tolerated dose ( MTD ), and…
- Trial name
- NCT05952128
- Testing
- Fluzoparib+ Dalpiciclib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Sarcoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Background: Vorinostat and bortezomib are anti-tumor drugs that have been approved by the Food and Drug Administration to treat different kinds of myeloma and lymphoma in adults.
- Conditions
- Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
- Trial name
- NCT01132911
- Testing
- Vorinostat (SAHA), Velcade (PS-341, Bortezomib)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01189253
- Testing
- doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis
- Where
- 43 sites in United States, Austria and 11 more
- Volunteers
- 133 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Sarcoma
Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00002539
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 16 sites in Belgium, Denmark and 6 more
- Volunteers
- 214 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma,Soft Tissue
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease…
- Trial name
- INVINCIBLE-3 (NCT06263231)
- Testing
- INT230-6, Eribulin, Trabectedin
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 333 people
- Sponsor
- Intensity Therapeutics, Inc.
Sarcoma, Kaposi, HIV Infections
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00002212
- Testing
- Bexarotene
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ligand Pharmaceuticals
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT02048722
- Testing
- regorafenib
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Osteosarcoma, Paget's Disease
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response…
- Conditions
- Osteosarcoma, Paget's Disease, Ewing Sarcoma
- Trial name
- NCT01882231
- Testing
- DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphomas
R Retreatment in 1st Relapsed DLBCL
It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.
- Trial name
- NCT00980304
- Testing
- Rituximab
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Genetic Signature in Development of Sarcomas
Validation of a Genetic Signature to Predict the Development of Sarcomas
The aim of the SARI study was to describe biomarkers of predisposition to the development of sarcomas in irradiated territory. This study included 120 patients with sarcoma in irradiated territory and 240 patients who had been…
- Trial name
- PREDISARC (NCT03625791)
- Testing
- blood sample
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Georges Francois Leclerc